Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Enterprise Value (2016 - 2026)

IGC Pharma has reported Enterprise Value over the past 16 years, most recently at -$1.1 million for Q3 2025.

  • Quarterly Enterprise Value rose 26.91% to -$1.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Sep 2025, up 26.91% year-over-year, with the annual reading at -$405000.0 for FY2025, 66.19% up from the prior year.
  • Enterprise Value was -$1.1 million for Q3 2025 at IGC Pharma, down from -$454000.0 in the prior quarter.
  • Over five years, Enterprise Value peaked at -$405000.0 in Q1 2025 and troughed at -$14.6 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$3.1 million (2023), against an average of -$5.4 million.
  • Year-over-year, Enterprise Value crashed 302.32% in 2021 and then skyrocketed 75.79% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$11.9 million in 2021, then surged by 57.85% to -$5.0 million in 2022, then skyrocketed by 72.62% to -$1.4 million in 2023, then soared by 65.89% to -$470000.0 in 2024, then plummeted by 140.43% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Enterprise Value are -$1.1 million (Q3 2025), -$454000.0 (Q2 2025), and -$405000.0 (Q1 2025).